Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,280 | -2,810 | -14,287 | -10,844 | -7,639 |
| Depreciation Amortization | 12 | 6 | 7 | 2 | 1 |
| Accounts payable and accrued liabilities | -704 | -350 | 828 | 22 | 290 |
| Other Working Capital | -1,473 | -1,162 | 1,619 | 2,082 | 1,199 |
| Other Operating Activity | 867 | 380 | -344 | 300 | -47 |
| Operating Cash Flow | $-7,578 | $-3,936 | $-12,178 | $-8,438 | $-6,196 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -8 | -93 | -86 | N/A |
| Investing Cash Flow | $-16 | $-8 | $-93 | $-86 | $0 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 16,000 | N/A | 5,789 | 5,789 | 5,789 |
| Other Financing Activity | -1,311 | 14,710 | -649 | -649 | -649 |
| Financing Cash Flow | $14,689 | $14,710 | $5,140 | $5,140 | $5,140 |
| Exchange Rate Effect | -7 | -2 | -8 | -9 | -5 |
| Beginning Cash Position | 21,648 | 21,648 | 28,787 | 28,787 | 28,787 |
| End Cash Position | 28,736 | 32,411 | 21,648 | 25,394 | 27,725 |
| Net Cash Flow | $7,088 | $10,763 | $-7,139 | $-3,393 | $-1,061 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,578 | -3,936 | -12,178 | -8,438 | -6,196 |
| Capital Expenditure | -16 | -8 | -93 | -86 | 0 |
| Free Cash Flow | -7,593 | -3,944 | -12,271 | -8,524 | -6,196 |